Shares in Aspen Pharmacare soared by more than 20% at the close of December, following a major strategic pivot. Africa’s largest drugmaker announced a landmark agreement to sell its entire Asia-Pacific (APAC) operations – excluding China – to Australia’s BGH Capital for A$2.37 billion (around R26.5 billion). The Aspen APAC divestment comes after an unsolicited offer from the private equity…